Widely used Painkiller Tramadol Questioned for Effectiveness, Linked to Increased Health Risks
Millions of French patients-over 5 million, according to health insurance data-might potentially be taking a pain medication whose benefits are now under serious scrutiny. A new study published in the British Medical Journal casts doubt on the effectiveness of tramadol for chronic pain and highlights a significantly increased risk of adverse effects, including potentially life-threatening heart problems.
Danish researchers conducted the first comprehensive synthesis of studies examining tramadol use for all types of chronic pain, with a particular focus on side effects. their findings reveal “limited analgesic benefits and an increased risk of harm,” leading them to conclude that the potential risks likely outweigh the drugS modest advantages. The study estimates tramadol provides onyl a slight reduction in pain levels-below what is considered a meaningful difference compared to a placebo-despite being prescribed for moderate to severe pain.
researchers found the risk of adverse effects from tramadol is twice as high as with placebos, specifically citing concerns about coronary heart disease and heart failure. “The use of tramadol for chronic pain should be reconsidered, favoring safer alternatives,” the authors assert.
dr. Janus Jakobsen, lead author of the study, advised patients to “consult their doctor to determine the most appropriate treatment for their condition,” in a recent CNN report.
This study adds to existing concerns about tramadol.France has already implemented measures to curb misuse and addiction, including limiting prescriptions to a maximum of three months and requiring secure prescriptions. However, tramadol remains the painkiller most frequently implicated in analgesic-related deaths in France, surpassing even morphine and codeine. Health officials recommend it be prescribed only after other options have been explored.
